Life expectancy for someone with ataxia depends almost entirely on which type of ataxia they have, because “ataxia” is not a single disease. It is an umbrella term covering dozens of conditions that impair coordination, and survival ranges from near-normal in some late-onset forms to severely shortened in others. A person with a mild, late-onset spinocerebellar ataxia may live into their seventies or eighties, while someone with Friedreich’s ataxia has historically faced a median lifespan in the late thirties. The type, the age symptoms begin, the organs involved, and increasingly the treatments available all shape the outlook.
Friedreich’s Ataxia
Friedreich’s ataxia (FA) is the most common inherited ataxia and one of the most studied. It typically appears in childhood or adolescence and progressively affects the nervous system, the heart, and sometimes glucose metabolism. Older literature put the average age of death at about 37.5 years, with a wide range from childhood to the early seventies, reflecting how variable the disease can be from person to person.1PubMed Central. Mortality in Friedreich’s Ataxia A Brazilian cohort found a similar figure, with a mean age at death of 33 years among those who had died.2PubMed. Survival in Brazilian Patients with Friedreich´s Ataxia
More recent prospective data paint a somewhat more encouraging picture. A study tracking patients over time found a 10-year cumulative survival rate of 87 percent, suggesting that many people with FA live well beyond a decade after diagnosis.3PubMed. Predictors of Survival in Friedreich’s Ataxia: A Prospective Cohort Study The gap between older and newer data probably reflects both better cardiac surveillance and improvements in supportive care. Still, heart disease remains the primary threat. About 59 percent of deaths in FA are caused by cardiac dysfunction, most commonly congestive heart failure and arrhythmias, with another 3 percent likely cardiac-related as well.4PubMed. Mortality in Friedreich ataxia This means that cardiac monitoring is not optional for anyone with FA; it is the single most important factor in extending life.
Spinocerebellar Ataxias
The spinocerebellar ataxias (SCAs) are a group of dominantly inherited conditions, and there are more than 40 known genetic subtypes. They tend to begin in adulthood, and their survival profiles differ considerably. A large European longitudinal study reported 10-year survival rates of 57 percent for SCA1, 74 percent for SCA2, 73 percent for SCA3, and 87 percent for SCA6.5PubMed. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study SCA1 stands out as the most aggressive of the common subtypes, with clearly shorter survival than the rest.
A separate study looking at parental age at death found that parents carrying polyglutamine-expansion SCAs (the group that includes SCA1, 2, 3, 6, and 7) had a median age at death of 68 years, compared to 80 years for parents with other, non-polyglutamine SCAs.6PubMed Central. Survival and severity in dominant cerebellar ataxias Among the polyglutamine SCAs, survival was comparable for SCA2, 3, 6, and 7, but significantly shorter for SCA1. SCA6, which tends to begin later in life and progress slowly, is generally considered the mildest of these subtypes, and many people with SCA6 live into their seventies or beyond.
These numbers underscore a point that sometimes gets lost: not all SCAs carry the same prognosis. If you have been told you have “a spinocerebellar ataxia,” the specific genetic subtype matters enormously for what to expect.
Ataxia-Telangiectasia
Ataxia-telangiectasia (A-T) is a childhood-onset condition caused by mutations in the ATM gene, and it affects much more than just coordination. It compromises the immune system, raises cancer risk dramatically, and causes progressive neurological deterioration. People with classic A-T generally die in the second or third decade of life, and those who survive longer face mounting complications: pulmonary disease, endocrine problems, cardiovascular issues, and eventual immobility with contractures.7PubMed Central. Classic ataxia-telangiectasia: the phenotype of long-term survivors
The mortality rate compared to the general population is strikingly elevated. One large cohort found a standardized mortality ratio of 24.6 overall, meaning people with A-T die at roughly 25 times the rate of age-matched peers. Among those who developed cancer, that ratio climbed to about 233.8Journal of Allergy and Clinical Immunology. Cancer spectrum, treatments, toxicities, and germline ATM genotype correlations in a large cohort of individuals with ataxia-telangiectasia Aspiration is another serious concern. Swallowing dysfunction worsens with age in A-T, and silent aspiration, where material enters the airway without triggering a cough, is common, particularly in teenagers and young adults.
Multiple System Atrophy With Cerebellar Features
Multiple system atrophy (MSA) is a neurodegenerative condition that can present with prominent ataxia, known as MSA-C (cerebellar type), or with parkinsonism (MSA-P). It is not an inherited ataxia but a sporadic one, meaning it arises without a clear genetic cause. MSA generally appears after age 50 and progresses more rapidly than most other ataxias. The median survival from symptom onset is about 8 to 9 years, with no significant difference between the cerebellar and parkinsonian subtypes.9PubMed Central. Multiple System Atrophy: Prognostic Indicators of Survival
Progression in MSA is driven in part by autonomic nervous system failure, which affects blood pressure regulation, bladder function, and breathing during sleep. One prospective cohort study found that the severity of orthostatic hypotension, the blood pressure drop that occurs on standing, was a major predictor of poorer survival.10PubMed. Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study MSA is one of the more sobering diagnoses in the ataxia world. It is resistant to most treatments and tends to progress faster than people expect.
Acquired and Immune-Related Ataxias
Not all ataxias are genetic, and the survival picture for acquired forms is entirely different. Alcohol-related cerebellar degeneration, one of the most common acquired ataxias, is not inherently fatal. People who stop drinking can recover some balance and coordination over time, though full recovery is unusual. Long-term abstinence improves ataxia, especially when the person can use visual cues for balance, but standing balance without visual input may remain impaired even years after quitting.11PubMed Central. Persistent but less severe ataxia in long-term vs. short-term abstinent alcoholic men and women: a cross-sectional analysis The life expectancy in these cases depends less on the ataxia itself and more on whether the person continues drinking and develops other alcohol-related organ damage.
Paraneoplastic cerebellar degeneration is a different story. This occurs when the immune system, responding to a cancer elsewhere in the body, mistakenly attacks the cerebellum. Survival hinges primarily on the underlying cancer rather than the neurological damage. In one long-term study, patients whose paraneoplastic ataxia was linked to breast cancer had a median survival of about 100 months, while those with gynecologic cancers survived a median of only 22 months.12PubMed. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies In these cases, the ataxia is disabling but the cancer drives the prognosis.
What Actually Kills People With Ataxia
Across many types of ataxia, the ultimate causes of death cluster around a few organ systems. In Friedreich’s ataxia, the heart is the primary concern, as described above. In other cerebellar ataxias, aspiration pneumonia is a leading killer. As coordination deteriorates, so does the ability to swallow safely and to cough effectively when something goes down the wrong pipe. Research shows that people with cerebellar ataxia have substantially weakened voluntary cough function, with peak expiratory flow rates less than half those of healthy individuals.13PubMed Central. Sensorimotor Cough Dysfunction in Cerebellar Ataxias When the cough reflex cannot clear aspirated material, repeated lung infections follow, and these can become fatal.
Falls are another underappreciated contributor to morbidity and mortality. A serious fall can lead to a hip fracture or head injury that triggers a cascade of complications, especially in someone already weakened by neurological disease. Immobility itself raises the risk of blood clots, pressure sores, and further deconditioning. The progressive loss of independence in many ataxias means that people spend years relying on wheelchairs and assistive care, and the medical complications of immobility accumulate.
Treatments That May Change the Outlook
For decades, there were no disease-modifying treatments for any inherited ataxia. That changed in 2023 when omaveloxolone became the first drug approved by the FDA specifically for Friedreich’s ataxia.14PubMed. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia The drug works by activating a cellular pathway that helps protect against oxidative stress, which is a key driver of damage in FA. In an open-label extension study following patients for about four years, those on omaveloxolone showed slower rates of disease progression compared to what would be expected from the natural course of the disease. A real-world observational study of adults with FA found similar early results, with no significant progression during treatment and no patients discontinuing due to side effects at last follow-up.15PubMed Central. Early experience on omaveloxolone in adult patients with Friedreich’s ataxia: a real-world observational study
Whether slowing progression will translate into meaningfully longer life remains to be seen. The drug has not yet been studied long enough to show a survival benefit, but stabilizing heart function and delaying wheelchair dependence could plausibly push life expectancy upward over time. For the dominant SCAs, antisense oligonucleotide therapy is being explored. In mouse models of SCA2, an antisense oligonucleotide that reduces the production of the disease-causing protein improved motor function and delayed symptom onset.16PubMed Central. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2 Human trials for this approach are still in early stages, but the concept of silencing or reducing the toxic protein is being pursued across multiple SCA subtypes.
Intensive rehabilitation also appears to slow things down, at least for a while. A seven-year follow-up study of patients with hereditary pure cerebellar ataxia found that annual intensive rehabilitation kept coordination scores stable for up to six years, which was slower than the expected natural rate of decline. Balance function, however, began deteriorating from the third year onward, suggesting that coordination and balance may respond to rehab on different timelines.17PubMed Central. Long-Term Effects of Annual Intensive Rehabilitation in Patients with Hereditary Pure Cerebellar Ataxia: A 7-year Follow-up Study Rehabilitation does not cure anything, but maintaining function for additional years can meaningfully affect quality of life and delay the complications of immobility.
Blood Markers That Predict How Fast Things Will Progress
One of the challenges with ataxia is that two people with the same genetic diagnosis can progress at very different rates. Researchers have been looking for blood-based biomarkers that could help predict who will decline faster. Neurofilament light chain (NfL), a protein released when nerve cells are damaged, is emerging as one such marker. In spinocerebellar ataxia carriers, higher NfL levels in the blood at baseline predicted both greater cerebellar shrinkage and faster clinical progression over follow-up.18PubMed. Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia
The same marker shows promise in ataxia-telangiectasia, where NfL levels correlated with disease severity scores and with wheelchair dependence.19PubMed Central. Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia NfL is not specific to ataxia; it goes up in many neurodegenerative conditions. But its practical value lies in being a simple blood test that could eventually help doctors identify patients who need more aggressive monitoring or who might be the best candidates for emerging therapies. It is also useful in clinical trials, where it can serve as an objective measure of whether a treatment is actually slowing nerve damage.
Mortality Trends and Disparities
Hereditary ataxia mortality in the United States has been rising. A retrospective analysis of two decades of death data (2000 through 2020) found increasing mortality rates across both sexes, with consistently higher death rates among males. The most striking finding was the disparity across racial groups: the largest relative increases occurred among Black or African American individuals. Geographically, the western United States saw the biggest relative rise.20PubMed Central. Trends and Disparities in Mortality from Hereditary Ataxia in United States, 2000-2020: A Retrospective Analysis with Projections to 2050
The reasons behind these disparities are not fully understood. Some of the overall rise may reflect better diagnosis rather than a true increase in disease frequency, since genetic testing has become far more accessible over the past two decades. But the racial and geographic disparities point toward differences in access to specialty neurology care, cardiac monitoring, and supportive services. For a group of diseases where proactive management of complications like heart failure and aspiration risk can extend life by years, unequal access to that management translates directly into unequal survival.
Why “Average Life Expectancy” Can Be Misleading
When people look up life expectancy numbers for ataxia, they often find a single figure and treat it as a prediction. But the ranges within each ataxia type are enormous. Friedreich’s ataxia, for instance, has documented ages at death ranging from childhood to over 70. Part of this spread comes from genetic variability: in FA, the length of the GAA repeat expansion in the frataxin gene correlates roughly with disease severity and age of onset. Someone with a shorter expansion may not develop symptoms until their twenties and progress slowly, while someone with a very long expansion might be in a wheelchair before adolescence.
Onset age is one of the strongest predictors across nearly all ataxia types. Earlier onset generally means faster progression and shorter survival, though there are exceptions. In the SCAs, the number of CAG repeats influences both when symptoms start and how quickly they advance, but even within a family carrying the same mutation, there can be meaningful variation from one generation to the next due to a phenomenon called anticipation, where the repeat tends to expand when passed from parent to child.
Comorbidities also shift the picture. Someone with Friedreich’s ataxia who develops diabetes alongside cardiomyopathy faces a different trajectory than someone whose heart remains relatively stable. In ataxia-telangiectasia, whether a person develops cancer changes the prognosis dramatically. And in any ataxia, the quality of swallowing management, respiratory care, and fall prevention can mean the difference between dying from a preventable complication and living years longer. The published averages are useful for understanding the general landscape, but they describe populations, not individuals.